atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer Post published:November 29, 2022 Post category:Press Release
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference Post published:November 28, 2022 Post category:Press Release
Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022 Post published:November 23, 2022 Post category:Press Release
Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing for atai’s PCN-101 Results; Tactogen Launches Community Funding Round Post published:November 19, 2022 Post category:Psychedelic Bulletin
MIND CURE ENTERS INTO BINDING LETTER OF INTENT WITH LNG ENERGY GROUP Post published:November 18, 2022 Post category:Press Release
MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD Post published:November 17, 2022 Post category:News/Press Release
Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai’s PCN-101 Phase 2a Readout Post published:November 17, 2022 Post category:Analysis
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment Post published:November 17, 2022 Post category:Press Release
FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH Post published:November 17, 2022 Post category:Press Release
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market Post published:November 17, 2022 Post category:Press Release